Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
about
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EOsteopontin Deficiency Alters Biliary Homeostasis and Protects against Gallstone FormationEffects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.Plasma Apolipoprotein A-V Predicts Long-term Survival in Chronic Hepatitis B Patients with Acute-on-Chronic Liver Failure.The metabolism of lipoprotein (a): an ever-evolving story.Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.
P2860
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
description
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@en
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@nl
type
label
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@en
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@nl
prefLabel
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@en
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@nl
P2093
P2860
P1476
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
@en
P2093
Antonio Hernandez-Ono
Byoung Moon
Colleen Ngai
Daniel S Donovan
Gissette Reyes-Soffer
Henry N Ginsberg
Jhonsua Jimenez
Joseph Obunike
Marija Dionizovik-Dimanovski
Nelson Fontanez
P2860
P304
P356
10.1126/SCITRANSLMED.AAD2195
P407
P577
2016-01-01T00:00:00Z